header banner
WORLD

Johnson & Johnson in discussion with FDA regarding COVID-19 vaccine side effects

July 13: Johnson & Johnson (JNJ.N) said on Monday it was in discussions with the U.S. Food and Drug Administration a...
By Reuters

July 13: Johnson & Johnson (JNJ.N) said on Monday it was in discussions with the U.S. Food and Drug Administration about rare cases of a neurological disorder, Guillain-Barré syndrome, that have been reported following vaccination with the Janssen COVID-19 vaccine.


The chance of having Guillain-Barré syndrome occur is very low and the rate of reported cases exceeds the background rate by a small degree, J&J said. (https://bit.ly/3katP1r)


Related story

Side effects from COVID-19 booster shots more common than from...


The statement follows a Washington Post report on Monday, which said the FDA was expected to announce a new warning on J&J's coronavirus vaccine related to a rare autoimmune disorder.


Guillain-Barré syndrome is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system, or the network of nerves located outside of the brain and spinal cord.

Related Stories
Coronavirus

FDA says benefits outweigh risks for Pfizer/BioNTe...

WORLD

Johnson & Johnson COVID-19 vaccine batch fails qua...

WORLD

As India readies vaccine strategy, Modi warns of p...

Coronavirus

Pfizer's COVID-19 shot causes mostly mild side eff...

SOCIETY

‘Johnson and Johnson’ vaccine being administered i...